

- (32) NIMETAZEPAM;
- (33) NITROZEPAM;
- (34) NORDIAZEPAM;
- [(8A)] (35) Oxazepam;
- (36) OXAZOLAM;
- [(9)] (37) Paraldehyde;
- [(10)] (38) Petrichloral;
- [(11)] (39) Phenobarbital;
- (40) PINAZEPAM;
- (41) PRAZEPAM;
- (42) TEMAZEPAM;
- (43) TETRAZEPAM;
- (44) TRIAZOLAM;

b. Any material, compound, mixture, or preparation which contains any quantity of the following substances including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible:

- (1) Fenfluramine.

c. Any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:

- (1) Diethylpropion.
- (2) Pemoline (including organometallic complexes and chelates thereof).
- (3) Phentermine.

d. The Department may except by rule any compound, mixture, or preparation containing any depressant substance listed in subsection (a) from the application of all or any part of this act if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a depressant effect on the central nervous system.

(e) Schedule V - In determining that a substance comes within this schedule, the Department shall find:

- 1. A low potential for abuse relative to the substances listed in Schedule IV; and
- 2. Currently accepted medical use in the United States; and
- 3. Limited physical dependence and/or psychological dependence liability relative to the substances listed in Schedule IV.